CAMBRIDGE, Mass.--(BUSINESS WIRE)--Platelet BioGenesis, Inc. (PBG), the leader in stem cell-derived, on-demand human platelets (PLTs+™) and platelet-based therapeutics, today announced that it has signed a lease for 18,000 square feet of lab space at 65 Grove Street in the emerging biotech hotbed of Watertown, Mass. The space is being built-to-purpose to provide the physical infrastructure necessary for the company to scale its unique stem cell-derived platelet manufacturing platform, advance its core program to the clinic and establish proof of concept for platelet-based therapeutics.
“With a burgeoning life sciences ecosystem of its own, easy accessibility to the biotech cluster in Cambridge and high-quality space for reasonable rates, Watertown is an ideal location to establish PBG’s first stand-alone headquarters to support our ongoing growth,” said Sven Karlsson, co-founder, and chief operating officer of Platelet BioGenesis.
The announcement of the lease signing follows on the heels of other recent milestones for the rapidly advancing company, including naming a new President and CEO, Sam Rasty, Ph.D., and adding biotech industry veteran, Richard Murray, Ph.D., as a new independent board member.
About Platelet BioGenesis
Platelet BioGenesis (PBG) has created the only platform that can generate human platelets at scale. The stem cell-derived, on-demand platelets will be the first donor-independent source of platelets to address the chronic shortage worldwide. The company is also developing platelet-based therapeutics, a new treatment modality for cancer and other life-threatening diseases. PBG’s platform is patented and cGMP-compliant. The company was spun out of Harvard University and has received venture funding from Qiming Venture Partners USA and other investors and attained grant funding from the Massachusetts Life Sciences Center, the National Institutes of Health and the U.S. Department of Defense. Learn more at plateletbiogenesis.com and follow us on Twitter @plateletbio.